Travere CMO Jula Inrig sells company shares

Travere Therapeutics, Inc. Chief Medical Officer Jula Inrig reported planned sales of company stock.

Rhea-AI Filing Summary

Travere Therapeutics, Inc. Chief Medical Officer Jula Inrig reported planned sales of company stock. On February 4, 2026, Inrig sold 1,547 Travere common shares at a weighted average price of $32.11 and an additional 232 shares at a weighted average price of $32.85.

These transactions were made under a written trading plan adopted on May 28, 2025 that meets Rule 10b5-1(c) requirements and include shares sold to cover tax obligations from vesting restricted stock units. Following these sales, Inrig directly held 105,706 Travere common shares.

Insider Trade Summary

Net Seller: 1,779 shares

Net Sell 2 txns

Insider Inrig Jula

Role CHIEF MEDICAL OFFICER

Sold 1,779 shs ($57K)

Type	Security	Shares	Price	Value
Sale	Common Stock	1,547	$32.11	$50K
Sale	Common Stock	232	$32.85	$8K

Holdings After Transaction: Common Stock — 105,706 shares (Direct)

Footnotes (3)

1. F1. This sale was made pursuant to a written plan adopted on May 28, 2025, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of restricted stock units.
2. F2. The weighted average sale price for the transaction reported was $32.11, and the range of prices were between $31.65 and $32.61. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.
3. F3. The weighted average sale price for the transaction reported was $32.85, and the range of prices were between $32.80 and $32.90. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Travere Therapeutics (TVTX) report for Jula Inrig?

Travere Therapeutics reported that Chief Medical Officer Jula Inrig sold company common stock on February 4, 2026. She sold 1,547 shares at a weighted average price of $32.11 and 232 shares at a weighted average of $32.85 in two separate transactions.

How many Travere Therapeutics (TVTX) shares does Jula Inrig own after this Form 4?

After the reported sales, Chief Medical Officer Jula Inrig directly beneficially owned 105,706 Travere Therapeutics common shares. This figure reflects her holdings following both February 4, 2026 transactions disclosed in the Form 4 insider trading report.

Were Jula Inrig’s Travere Therapeutics (TVTX) stock sales under a 10b5-1 plan?

Yes. The filing states the sales were made under a written trading plan adopted on May 28, 2025 that meets Rule 10b5-1(c) requirements, indicating a pre-arranged, systematic approach to selling shares over time.

What were the sale prices in Jula Inrig’s Travere Therapeutics (TVTX) Form 4?

The first transaction had a weighted average sale price of $32.11, with trades between $31.65 and $32.61. The second had a weighted average price of $32.85, with trades between $32.80 and $32.90, as detailed in the Form 4 footnotes.

Did Jula Inrig sell Travere Therapeutics (TVTX) shares to cover taxes?

Yes. The filing explains that the reported sale activity includes shares sold to cover tax obligations arising when restricted stock units vested, alongside other sales executed under the Rule 10b5-1 trading plan adopted in May 2025.

Is Jula Inrig a major shareholder or officer at Travere Therapeutics (TVTX)?

According to the Form 4, Jula Inrig is an officer of Travere Therapeutics, serving as Chief Medical Officer. She is not listed as a director or a 10% owner in this particular insider ownership and transaction report.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/05/2026 - 04:05 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Inrig Jula

(Last) (First) (Middle)

C/O TRAVERE THERAPEUTICS, INC.

3611 VALLEY CENTRE DRIVE, SUITE 300

(Street)

SAN DIEGO CA 92130

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Travere Therapeutics, Inc. [ TVTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CHIEF MEDICAL OFFICER

3. Date of Earliest Transaction (Month/Day/Year)
02/04/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/04/2026		S(1)		1,547	D	$32.11(2)	105,938	D
Common Stock	02/04/2026		S(1)		232	D	$32.85(3)	105,706	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. This sale was made pursuant to a written plan adopted on May 28, 2025, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of restricted stock units.

2. The weighted average sale price for the transaction reported was $32.11, and the range of prices were between $31.65 and $32.61. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.

3. The weighted average sale price for the transaction reported was $32.85, and the range of prices were between $32.80 and $32.90. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.

	/s/ Elizabeth E. Reed, Attorney-in-Fact	02/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.